Literature DB >> 2944969

Large scale separation of human bone marrow by counterflow centrifugation elutriation.

S J Noga, C A Cremo, S C Duff, C L Schwartz, A Melaragno, C I Civin, A D Donnenberg.   

Abstract

Counterflow centrifugation elutriation (CCE) has been used to separate moderate quantities of bone marrow (BM) into distinct cell populations for further in vitro investigation. Recently, this technique was employed to reduce the incidence of graft-versus-host disease (GVHD) in human allogeneic bone marrow transplantation (BMT) by removing the majority of mature lymphocytes from the graft. Unfortunately, current methods employing the small (J6-B) elutriator rotor require time consuming preseparation steps and multiple runs. We report our experience with a fixed rotor speed, two-flow rate elutriation procedure using the new Beckman JE-10X rotor system which can separate more than 10(10) nucleated BM cells in 30 min. Three fractions were obtained which differed in size, morphology, and immunologic capacity. The large cell fraction is suitable for allogeneic BMT since it is radically depleted of mature T lymphocytes and retains high clonogeneic capacity.

Entities:  

Mesh:

Year:  1986        PMID: 2944969     DOI: 10.1016/0022-1759(86)90168-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

1.  High incidence of graft failure in children receiving CD34+ augmented elutriated allografts for nonmalignant diseases.

Authors:  C H McDonough; D A Jacobsohn; G B Vogelsang; S J Noga; A R Chen
Journal:  Bone Marrow Transplant       Date:  2003-06       Impact factor: 5.483

2.  TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications.

Authors:  Maria A Papadaki; Alexia Monastirioti; Christina A Apostolopoulou; Despoina Aggouraki; Chara Papadaki; Kleita Michaelidou; Maria Vassilakopoulou; Katerina Alexakou; Dimitrios Mavroudis; Sofia Agelaki
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.